177477-60-0

Basic information

• Product Name: 1,2-Benzenediamine, 3-methoxy-N1-methyl-
• Synonyms: 1,2-Benzenediamine, 3-methoxy-N1-methyl-;3-methoxy-N1-methylbenzene-1,2-diamine;3-methoxy-N1-methyl-1,2-benzenediamine
• CAS NO: 177477-60-0
• Molecular Formula: C₈H₁₂N₂O
• Molecular Weight: 152.19
• Mol File: 177477-60-0.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,2-Benzenediamine, 3-methoxy-N1-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-Benzenediamine, 3-methoxy-N1-methyl-(177477-60-0)
• EPA Substance Registry System: 1,2-Benzenediamine, 3-methoxy-N1-methyl-(177477-60-0)

Safety Data

• Hazardous Substances Data: 177477-60-0(Hazardous Substances Data)

Usage

Structure

A derivative of 1,2-benzenediamine with a methoxy group and a methyl group on the nitrogen atom

Applications

Intermediate in the synthesis of dyes, pigments, and pharmaceuticals; hair dye ingredient

Hazardous properties

Causes skin and eye irritation; harmful if swallowed or inhaled

Classification

Hazardous material

Handling and storage

Requires caution and proper safety measures

Upstream product

• 158461-29-1 tert-butyl N-(2-nitro-3-methoxyphenyl)carbamate 
• 1143575-94-3 tert-butyl (3-methoxy-2-nitrophenyl)-(methyl)carbamate 
• 106837-96-1 (3-methoxy-2-nitrophenyl)-methylamine 
• 641-49-6 1-fluoro-3-methoxy-2-nitrobenzene 
• 1143575-95-4 (3-methoxy-2-nitrophenyl)-(methyl)amine 
• 4920-80-3 3-methoxy-2-nitrobenzoic acid 
• 177477-59-7 ethyl N-(3-methoxy-2-nitrophenyl)carbamate 

Downstream Products

• 33604-87-4 2-chloro-4-methoxy-1-methyl-1H-benzimidazole 
• 2095107-57-4 N1-(3-oxoisoindoline)benzoyl-N5-(2-fluoro-1-iminoethyl)-1-(4-methoxy-1-methylbenzo[d]imidazol-2-yl)-L-ornithine 
• 177477-61-1 1,2-dimethyl-4-methoxy-1H-benzimidazole 
• 177477-62-2 4-hydroxy-1,2-dimethyl-1H-benzimidazole 

Relevant articles and documents

COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS

The present invention relates to new medicament combinations which contain in addition to one or more PDE4-inhibitors (1) at least one EP4 receptor antagonist (2), as well as the use thereof for the treatment of preferably respiratory complaints such as particularly COPD, chronic sinusitis and asthma. The invention relates in particular to those medicament combinations which contain at least one EP4 receptor antagonist (2), in addition to one or more, preferably one, PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R3 denotes an optionally substituted, mono- or bicyclic, unsaturated, partly saturated or saturated heterocyclic group or an optionally substituted, mono- or bicyclic heteroaryland wherein R1 and R2 have the meanings given in claim 1, the preparation thereof and the use thereof for the treatment of respiratory complaints.

BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS

The present invention relates to benzoxazinone derivatives, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in treating disorders mediated by GlyT1, including neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.

QUINOXALINEDIONE DERIVATIVES

The present invention relates to compounds of formula (I) wherein X, Y, Z, R1, R2, R3 are as defined in claim 1, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diabete